期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Long-term survival of a HCC-patient with severe liver dysfunction treated with sorafenib 被引量:1
1
作者 Christoph Roderburg Jhenee Bubenzer +5 位作者 Michael Spannbauer Nicole do O andreas mahnken Tom Luedde Christian Trautwein Jens JW Tischendorf 《World Journal of Hepatology》 CAS 2010年第6期239-242,共4页
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver. Prognosis and treatment options are stage dependent. In general, prognosis of patients with unresectable HCC is poor, especially for those... Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver. Prognosis and treatment options are stage dependent. In general, prognosis of patients with unresectable HCC is poor, especially for those patients with impaired liver function. Whereas treatment with the novel molecular tyrosine kinase inhibitor sorafenib (Nexavar) was shown to result in prolonged survival in patients with preserved liver function, its' possible application in HCC-patients with strongly impaired liver function has not been clearly assessed. Here, we report on a 47-year-old male patient who presented with Child-Pugh class C liver cirrhosis and multifocal, non-resectable HCC. The patient was treated for 27 mo with Sorafenib, which was not associated with major drug-related side effects. During treatment, a reduction in tumour size of 24% was achieved, as assessed by regular CT scan. Moreover,within the 27 mo interval of stable tumour disease, liver function improved from Child-Pugh class C to class A. 展开更多
关键词 HEPATOCELLULAR carcinoma SORAFENIB Liver CIRRHOSIS CHILD-PUGH SCORE Long-term survival
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部